Kailera's GLP-1 drug meets main goal of late-stage trials
07/07/2026 12:06
Kailera's GLP-1 drug meets main goal of late-stage trials July 7 (Reuters) - Kailera Therapeutics KLRA.O said on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Recent news on Kailera Therapeutics
See all newsChina biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
China biotech's ingenuity extends to dealmaking
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Kailera Therapeutics Announces Completion Of Enrollment In Kainetic Global Phase 3 Clinical Program Of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection